Perioperative Chemotherapy With Bevacizumab for Colorectal Carcinomatosis
Ontology highlight
ABSTRACT: The Bev-IP trial is designed to assess the feasibility and efficacy of a combined treatment consisting of perioperative combination chemotherapy with the vascular endothelial growth factor A inhibitor bevacizumab and cytoreductive surgery with intraperitoneal oxaliplatin.
DISEASE(S): Carcinoma,Colorectal Neoplasms
PROVIDER: 2186592 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA